Uscom Inks SpiroSonic Pact With US eHealth Leader – Koneksa

Uscom Inks SpiroSonic Pact With US eHealth Leader - Koneksa

Uscom Limited (ASX: UCM) manufactures and develops cardiac monitoring devices. Today (7 February 2019) the company announced a distribution agreement to supply digital ultrasonic spirometers to leading US cardiovascular and pulmonary eHealth provider Koneksa Health.

The New York-based Koneksa Health has put an inaugural order for Uscom SpiroSonic Mobile devices. These Devices are being manufactured at Uscom Kft in Budapest. The delivery of this order is estimated to generate revenue to the tune of $140K. This order of Uscom SpiroSonic MOBILE spirometers will be to seed Koneksa’s US pulmonary monitoring market roll out. The nonexclusive agreement with Koneksa is for a period of two years with on-going renewal options, another step toward Uscom becoming a platform technology for the global eHealth market.

Koneksa is one of the foremost eHealth provider based out of New York, which utilises the multi-parametric physiologic sensors to detect cardiovascular, pulmonary and other signals. These signals are then attached to proprietary cloud-based software for analysis by remotely located physicians. This telemonitoring allows high volume data-analytics of cardiac and lung function, and soft signs such as motion and sleep monitoring. The Uscom SpiroSonic MOBILE digital spirometer is explicitly used, for accurate lung function monitoring of asthma, COPD and occupational lung disease. Koneksa’s flexible software platform improves the collection and representation of physiologic signals for Electronic Clinical Outcomes Assessment.

Executive Chairman of Uscom, Associate Professor Rob Phillips has said that Uscom SpiroSonic are one of the best digital spirometers and their application in pulmonary eHealth are intuitive due to their ultrasonic accuracy, simple disinfection, no consumables, and no daily calibration for temperature, pressure and humidity.

According to him, eHealth is the way of the future, and Koneksa is creating an outstanding interactive software platform that will provide access to cost-effective health delivery over the coming years. The eHealth proposition is founded on quality front end digital sensors to establish effectiveness, and Koneksa has chosen Uscom SpiroSonic devices for their asthma and COPD monitoring strategy.

Now let us quickly have a look at the company’s stock performance and the return it has posted over the last few months. The stock is currently trading at a price of $0.120 and is trading up by 4.348% during the day’s trade, with a market capitalisation of ~$15.83 Million. The counter opened the day at $0.13, which was also the day’s high & touched a day’s low of $0.12. The stock has provided a YTD return of -23.33% & also posted returns of -30.30%, -23.33% over the past six and three months period respectively. It had a 52-week high price of $0.290 and touched 52 weeks low of $0.110, with an average volume of 164,896 approximately.

Sponsored ad by Kalkine


This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.

Facebook Comments

Join Our Discussion

Start discussion with value Investors for ASX Stock Market Investment and Opinion.

6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report


Please enter your comment!
Please enter your name here